Hi Cancer Surveillance Community,
The Cancer PathCHART Team at the NCI Surveillance Research Program has received questions about when the 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List (CPC SMVL) standards (located at https://seer.cancer.gov/cancerpathchart/products.html) should be applied. This message is a reminder that the 2024 CPC SMVL standards should only be applied to cancer cases diagnosed January 1, 2024 and forward.
Before January 1, 2024, the 2023 resources should be used to determine how a site-morphology combination should be recorded. These 2023 standards can be found at https://seer.cancer.gov/registrars/guidelines.html and https://seer.cancer.gov/icd-o-3/.
If you have further questions about the project, please contact the Cancer PathCHART Team at NCICancerPathCHART@mail.nih.gov.
Alison on Behalf of the Cancer PathCHART Team
Alison L. Van Dyke, MD, PhD, FCAP
Data Quality, Analysis, and Interpretation Branch
Surveillance Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, 4E348
Rockville, MD 20850
If you are receiving this email outside of your typical working hours, I hope you feel no pressure to read or respond until your schedule and workload permit.